-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 2, 2021, AbbVie announced that JAK inhibitor Rinvoq (upadacitinib) had reached the primary and secondary endpoints
in Phase 3 clinical trials for patients with severe rheumatoid arthritis.
The results showed that the Rinvoq/MTX combination maintained a higher clinical remission rate and lower disease activity (low disease activity) over a three-year term compared to treatment with Humira/methotrexate (MTX), with more than a quarter of patients achieving clinical remission
In addition, a comprehensive security analysis found that Rinvoq's security
characteristics were consistent over a 4.
5-year follow-up period and no new security risks were observed.
Rinvoq is a daily oral selective JAK inhibitor that is being studied
in several immuno-mediated inflammatory diseases.
JAK family proteins play an important role in the pathophysiological process of immuno-mediated diseases, and in human cell testing, Rinvoq prioritizes the suppression of JAK1 signaling.
Earlier, AbbVie had announced that after 12 weeks of treatment, Phase 3 clinical trial SELECT-COMPARE
results showed that Rinvoq reached the main endpoint of ACR20 response and clinical remission.
Data released today show that compared with the active control group, the proportion of patients
Data on the long-term efficacy of Rinvoq in the SELECT-COMPARE trial (Image Source: Supplied)
Rheumatoid arthritis is a chronic, debilitating immune-mediated inflammatory disease affecting
an estimated 23.
7 million people worldwide.
As the most common autoimmune arthritis, it can
Note: There are limitations in the original text
Resources:
[1] New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress.
[2] AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress.
